-

BeFisetin® Announced the Global No.1 All-Natural Fisetin With SA-GRAS Status

NEW YORK--(BUSINESS WIRE)--Bonerge Lifescience, a trusted innovator in longevity ingredients, proudly announces a historic milestone: on April 2, 2025, its premium fisetin ingredient, BeFisetin®, has achieved Self-affirmed Generally Recognized as Safe (SA-GRAS) status in the United States. This landmark accomplishment positions Bonerge as the first company globally to secure GRAS certification for fisetin powder, setting a new global benchmark for safety and reliability in the next-generation anti-aging market.

BeFisetin: Establishing the Gold Standard to Address Chaos in the Fisetin Market

The current fisetin market is plagued by alarming quality inconsistencies. While vague claims of "Fisetin 98% HPLC" dominate as the mainstream specification, actual fisetin content in these products ranges only between 75%-85%, with significant impurities concealed under this ambiguous standard.

For plant extracts derived from non-edible sources, the removal of harmful components is critical. Fisetin, extracted from inedible Anacardiaceae plants, contains large amounts of toxic lacquer, waxes, and wood debris. Eliminating these impurities is essential to producing safe, high-quality fisetin. Yet, the absence of clear, stringent quality standards has made it impossible to verify purity, allowing low-quality products to flood the market.

Many suppliers exploit rudimentary testing methods to falsely label products as "98% HPLC," misleading consumers and perpetuating a cycle where inferior products overshadow genuine quality. This chaos forces brands to settle for subpar fisetin, stifling innovation in premium formulations.

Establishing a gold standard for fisetin quality has been Bonerge’s mission from the start. Recognizing the challenges—extensive R&D, industry-first breakthroughs, and short-term financial sacrifices—we named our product BeFisetin as a constant reminder: "To be or not to be" hinges on our commitment to redefine excellence in fisetin. BeFisetin is not just a product—it’s a pledge to restore integrity and drive progress in the fisetin industry.

What Defines the Gold Standard for Fisetin?

  • Safety First: SA-GRAS certification ensures systemic safety evaluation, a critical gateway for market entry.
  • Transparent Quality Metrics: BeFisetin guarantees 98% HPLC purity, 98% HPLC content, 99% total active ingredients, and <1% impurities, setting unmatched benchmarks for consistency and quality.
  • Ongoing Clinical Validation: Bonerge has completed the first double-blind, controlled clinical trial on BeFisetin’s efficacy in skin health, with results under analysis and pending publication. A second large-scale trial on sleep and immune health, approved by ethics committees in March, is now underway.

BeFisetin: The 1st All-Natural Fisetin to be Granted SA-GRAS

BeFisetin® is the first all-natural fisetin to attain SA-GRAS certification. For all dietary supplement ingredients, SA-GRAS represents a critical milestone, but its significance is unparalleled in advancing fisetin as a premium raw material. This certification sets the gold standard for the industry, requiring adherence to rigorous criteria: well-defined quality specifications, scientifically validated testing protocols, GMP-compliant manufacturing environments, and comprehensive safety assessments—all of which elevate fisetin from an underregulated botanical to a clinically trusted ingredient. By establishing these benchmarks, SA-GRAS not only ensures consumer safety but also paves the way for innovation in longevity-focused formulations.

“Beyond regulatory compliance, this accomplishment reflects our foundational commitment to scientific excellence and consumer safety—principles that drive every stage of our ingredient innovation,” stated Gloria, Product Manager of Bonerge. “SA-GRAS BeFisetin® provides brands with a scientifically validated ingredient that meets international regulatory requirements, enabling them to develop innovative products with assurance.”

A Vision for Trusted Longevity Foundation

The GRAS certification of BeFisetin® marks the beginning of Bonerge’s mission to redefine aging. By prioritizing rigorous science and consumer safety, Bonerge aims to foster transparency in the anti-aging market, and we are committed to providing scientifically grounded solutions that empower individuals to age healthily. As global interest in senotherapeutics grows, BeFisetin® stands at the forefront, offering brands a trusted, scalable ingredient to meet the rising demand for effective and safe longevity products.

Contacts

Cecilia Yang
sales@bonerge.com

Bonerge Lifescience


Release Versions

Contacts

Cecilia Yang
sales@bonerge.com

More News From Bonerge Lifescience

Bonerge Unveils StanYouth® CR3: A Revolutionary Anti-Aging Complex Merging TCM Wisdom and Cellular Science

NEW YORK--(BUSINESS WIRE)--StanYouth® CR3, Bonerge’s patented blend, merges TCM and science to deliver evidence-based beauty from within and oral beauty with proven skin care....

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combina...

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

NEW YORK--(BUSINESS WIRE)--Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market. Senolytics Research: Advancing the Science of Anti-Aging In recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest Univers...
Back to Newsroom